Women's Health · ContraceptiveRegulatory Approvalregulatorymid-term

Lupin's ANDA201446 for Levonorgestrel Receives FDA AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/3/2026, 6:03:09 AM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Lupin's receipt of Abbreviated Approval (AP) status for Levonorgestrel is significant as it positions the company to enhance its competitive stance in the contraceptive market. This development necessitates a review of market strategies by other players in the segment to maintain their market share. Regulatory context from FDA (FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies in the contraceptive segment. The strongest clinical anchor is Effect of Health Belief Model-Based Education on Cervical Cancer Knowledge and HPV Vaccine Attitudes in Women (ClinicalTrials.gov), moderate corpus alignment. In Women's Health · Contraceptive, 7 regulatory and 4 competitive items passed relevance filtering for Lupin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Glycerol Phenylbutyrate Application by Lupin (Humanexa Signals) — entity match (lupin). Secondary pressure from Teva's Sugammadex Sodium Receives FDA Approval Status. This approval may enhance Lupin's position in the contraceptive market, competing with other generic and branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL) (FDA). Entity match (levonorgestrel); Regulatory pathway relevance (nda). The AP status indicates a streamlined pathway for Lupin's product, which may influence future submissions and approvals in the contraceptive category.

Key Risks

Elevated medium regulatory exposure for Lupin could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Disparities in Emergency Contraceptive Metabolism Dictate Efficacy) could weigh on Lupin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The approval could lead to increased market share for Lupin, potentially affecting pricing strategies and revenue for both generic and branded contraceptive products.
Upside for Lupin may improve if Trends in ritodrine prescriptions among pregnant women in Japan: a nationwide descriptive analysis of an administrative hospital database from 2015 to 2024. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies in the contraceptive segment.

What Would Change This Assessment

This becomes more urgent if Monitor for market launch timelines and competitor responses in the contraceptive space.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (levonorgestrel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (levonorgestrel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIAZEPAM (ORIG)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Effect of Health Belief Model-Based Education on Cervical Cancer Knowledge and HPV Vaccine Attitudes in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Factors Influencing Fertility or Pregnancy Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sexual Health Advocacy for Guys - Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sample Collection From Healthy Volunteers for Assay Optimization
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Navigating Financial and Health-Related Social Needs in Adolescent and Young Adult Cancer Survivors (AYA-NAV)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Glycerol Phenylbutyrate Application by Lupin
Humanexa Signalshigh relevance
Entity match (lupin)
Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalsmedium relevance
Moderate corpus alignment
Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Baseline neutrophil-to-lymphocyte ratio and cumulative clinical pregnancy and obstetric/neonatal outcomes after IVF/ICSI in women with PCOS: exploratory analysis including sperm preservation method.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trends in ritodrine prescriptions among pregnant women in Japan: a nationwide descriptive analysis of an administrative hospital database from 2015 to 2024.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of a brief primary care intervention for post-traumatic stress disorder symptoms after critical illness on health-related quality of life - A secondary analysis of the PICTURE randomised contr
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Lupin
Levonorgestrel

Commercial impact

medium

The approval could lead to increased market share for Lupin, potentially affecting pricing strategies and revenue for both generic and branded contraceptive products.

Regulatory impact

medium

The AP status indicates a streamlined pathway for Lupin's product, which may influence future submissions and approvals in the contraceptive category.

What to watch

Monitor for market launch timelines and competitor responses in the contraceptive space.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.